JP2020182458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020182458A5 JP2020182458A5 JP2020078116A JP2020078116A JP2020182458A5 JP 2020182458 A5 JP2020182458 A5 JP 2020182458A5 JP 2020078116 A JP2020078116 A JP 2020078116A JP 2020078116 A JP2020078116 A JP 2020078116A JP 2020182458 A5 JP2020182458 A5 JP 2020182458A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cancer
- cell
- nucleic acid
- peptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 210000004027 cell Anatomy 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 239000013604 expression vector Substances 0.000 claims 11
- 108091008874 T cell receptors Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 108010028930 invariant chain Proteins 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192670P | 2015-07-15 | 2015-07-15 | |
| US62/192,670 | 2015-07-15 | ||
| GB1512369.8 | 2015-07-15 | ||
| GBGB1512369.8A GB201512369D0 (en) | 2015-07-15 | 2015-07-15 | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501316A Division JP6862411B2 (ja) | 2015-07-15 | 2016-07-14 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020182458A JP2020182458A (ja) | 2020-11-12 |
| JP2020182458A5 true JP2020182458A5 (enExample) | 2021-04-30 |
Family
ID=54013984
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501316A Active JP6862411B2 (ja) | 2015-07-15 | 2016-07-14 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020052558A Active JP7074367B2 (ja) | 2015-07-15 | 2020-03-24 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020059702A Active JP7239992B2 (ja) | 2015-07-15 | 2020-03-30 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020068264A Active JP7074369B2 (ja) | 2015-07-15 | 2020-04-06 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020071602A Active JP7074370B2 (ja) | 2015-07-15 | 2020-04-13 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020074570A Active JP7239993B2 (ja) | 2015-07-15 | 2020-04-20 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020078116A Pending JP2020182458A (ja) | 2015-07-15 | 2020-04-27 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020082964A Pending JP2020198875A (ja) | 2015-07-15 | 2020-05-11 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020086514A Active JP7205919B2 (ja) | 2015-07-15 | 2020-05-18 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020090207A Pending JP2021000078A (ja) | 2015-07-15 | 2020-05-25 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501316A Active JP6862411B2 (ja) | 2015-07-15 | 2016-07-14 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020052558A Active JP7074367B2 (ja) | 2015-07-15 | 2020-03-24 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020059702A Active JP7239992B2 (ja) | 2015-07-15 | 2020-03-30 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020068264A Active JP7074369B2 (ja) | 2015-07-15 | 2020-04-06 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020071602A Active JP7074370B2 (ja) | 2015-07-15 | 2020-04-13 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020074570A Active JP7239993B2 (ja) | 2015-07-15 | 2020-04-20 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020082964A Pending JP2020198875A (ja) | 2015-07-15 | 2020-05-11 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020086514A Active JP7205919B2 (ja) | 2015-07-15 | 2020-05-18 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2020090207A Pending JP2021000078A (ja) | 2015-07-15 | 2020-05-25 | 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (36)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EA201991444A1 (ru) | 2017-01-27 | 2019-12-30 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака |
| SI3573647T1 (sl) * | 2017-01-27 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka |
| WO2018138257A1 (en) * | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| CN110531077B (zh) * | 2018-05-25 | 2023-07-07 | 荣昌生物制药(烟台)股份有限公司 | 间皮素免疫组化检测试剂盒 |
| WO2020028562A1 (en) * | 2018-07-31 | 2020-02-06 | Loma Linda University | Snail sirna-loaded mesoporous silica nanoparticles |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| DE102019108125B4 (de) * | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| WO2020257922A1 (en) * | 2019-06-25 | 2020-12-30 | Université de Montréal | Novel tumor-specific antigens for ovarian cancer and uses thereof |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2022543687A (ja) * | 2019-08-09 | 2022-10-13 | イマティクス ユーエス，アイエヌシー． | ペプチド質量分析断片化を予測するための方法 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| US20220347261A1 (en) * | 2021-04-23 | 2022-11-03 | Vlp Therapeutics, Inc. | Galectin-targeting immunotherapy |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| CN113241177B (zh) * | 2021-05-19 | 2024-05-10 | 上海宝藤生物医药科技股份有限公司 | 一种评估免疫力水平的方法、装置、设备及存储介质 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023025851A1 (en) * | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN114657158B (zh) * | 2022-05-25 | 2022-10-21 | 深圳吉诺因生物科技有限公司 | Ido1相关疫苗及其应用 |
| GB202302709D0 (en) * | 2023-02-24 | 2023-04-12 | Genome Res Ltd | Method of identifying t cell recpetors of interest |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050175625A1 (en) * | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| AU2003299643A1 (en) * | 2002-12-04 | 2004-06-23 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| AU2005282489A1 (en) * | 2004-09-08 | 2006-03-16 | Cornell Research Foundation, Inc. | Cancer-testis antigens |
| US8404803B2 (en) | 2005-03-31 | 2013-03-26 | Chugai Seiyaku Kabushiki Kaisha | Cancer-associated antigen analogue peptides and uses thereof |
| PL1760089T3 (pl) * | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| PL1760088T3 (pl) | 2005-09-05 | 2008-10-31 | Immatics Biotechnologies Gmbh | Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA) |
| JP5543207B2 (ja) * | 2006-10-04 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用 |
| US8097242B2 (en) | 2006-10-05 | 2012-01-17 | The Board Of Trustees Of The University Of Arkansas | Target CA125 peptides for cancer immunotherapy |
| BRPI0813621A2 (pt) * | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| CN105566450A (zh) * | 2007-07-27 | 2016-05-11 | 伊玛提克斯生物技术有限公司 | 免疫疗法的新型免疫抗原表位 |
| WO2009032224A2 (en) * | 2007-08-29 | 2009-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inhibiting squamous cell carcinoma |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US9688991B2 (en) * | 2012-07-13 | 2017-06-27 | Albert Einstein College Of Medicine, Inc. | Aptamer-targetted antigen delivery |
| WO2014157692A1 (ja) * | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| TWI819228B (zh) * | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| PT3388075T (pt) * | 2015-03-27 | 2023-08-18 | Immatics Biotechnologies Gmbh | Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
-
2015
- 2015-07-15 GB GBGB1512369.8A patent/GB201512369D0/en not_active Ceased
- 2015-07-15 MY MYPI2018700111A patent/MY189596A/en unknown
-
2016
- 2016-07-14 US US15/209,845 patent/US9889159B2/en active Active
- 2016-07-14 NZ NZ739128A patent/NZ739128A/en not_active IP Right Cessation
- 2016-07-14 CA CA2992506A patent/CA2992506A1/en active Pending
- 2016-07-14 KR KR1020227017673A patent/KR20220075451A/ko not_active Ceased
- 2016-07-14 MD MDE20180524T patent/MD3322717T2/ro unknown
- 2016-07-14 EP EP20170212.3A patent/EP3705491A1/en active Pending
- 2016-07-14 HR HRP20201281TT patent/HRP20201281T1/hr unknown
- 2016-07-14 EP EP16739102.8A patent/EP3322717B1/en active Active
- 2016-07-14 CN CN202111534523.0A patent/CN114163501A/zh active Pending
- 2016-07-14 SG SG10202100291XA patent/SG10202100291XA/en unknown
- 2016-07-14 CR CR20200409A patent/CR20200409A/es unknown
- 2016-07-14 UA UAA201712985A patent/UA124875C2/uk unknown
- 2016-07-14 RS RS20200937A patent/RS60647B1/sr unknown
- 2016-07-14 MA MA41717A patent/MA41717A1/fr unknown
- 2016-07-14 SG SG10202100295RA patent/SG10202100295RA/en unknown
- 2016-07-14 MA MA42441A patent/MA42441B1/fr unknown
- 2016-07-14 LT LTEP16739102.8T patent/LT3322717T/lt unknown
- 2016-07-14 CN CN201680041146.8A patent/CN107922469A/zh active Pending
- 2016-07-14 JP JP2018501316A patent/JP6862411B2/ja active Active
- 2016-07-14 MX MX2018000543A patent/MX2018000543A/es unknown
- 2016-07-14 CR CR20200410A patent/CR20200410A/es unknown
- 2016-07-14 ME MEP-2020-159A patent/ME03808B/me unknown
- 2016-07-14 HU HUE16739102A patent/HUE049937T2/hu unknown
- 2016-07-14 DK DK16739102.8T patent/DK3322717T3/da active
- 2016-07-14 AU AU2016293047A patent/AU2016293047B9/en not_active Ceased
- 2016-07-14 CR CR20180027A patent/CR20180027A/es unknown
- 2016-07-14 WO PCT/EP2016/066706 patent/WO2017009400A1/en not_active Ceased
- 2016-07-14 CR CR20200408A patent/CR20200408A/es unknown
- 2016-07-14 CA CA3221097A patent/CA3221097A1/en active Pending
- 2016-07-14 BR BR122023024959-3A patent/BR122023024959A2/pt unknown
- 2016-07-14 SG SG10202100296PA patent/SG10202100296PA/en unknown
- 2016-07-14 SG SG10202100292VA patent/SG10202100292VA/en unknown
- 2016-07-14 PT PT167391028T patent/PT3322717T/pt unknown
- 2016-07-14 SG SG10202100297QA patent/SG10202100297QA/en unknown
- 2016-07-14 IL IL292131A patent/IL292131A/en unknown
- 2016-07-14 SI SI201630868T patent/SI3322717T1/sl unknown
- 2016-07-14 PL PL16739102T patent/PL3322717T3/pl unknown
- 2016-07-14 SG SG10202100294WA patent/SG10202100294WA/en unknown
- 2016-07-14 SG SG10202100298SA patent/SG10202100298SA/en unknown
- 2016-07-14 IL IL308200A patent/IL308200A/en unknown
- 2016-07-14 PE PE2018000052A patent/PE20180693A1/es unknown
- 2016-07-14 BR BR112017028558-4A patent/BR112017028558A2/pt not_active Application Discontinuation
- 2016-07-14 KR KR1020187000652A patent/KR20180030506A/ko not_active Ceased
- 2016-07-14 EA EA201890027A patent/EA201890027A1/ru unknown
- 2016-07-14 MA MA050542A patent/MA50542A/fr unknown
- 2016-07-14 PE PE2023001339A patent/PE20240645A1/es unknown
- 2016-07-14 ES ES16739102T patent/ES2807832T3/es active Active
-
2017
- 2017-11-15 US US15/813,610 patent/US10463696B2/en active Active
-
2018
- 2018-01-02 IL IL256697A patent/IL256697B/en unknown
- 2018-01-03 PH PH12018500005A patent/PH12018500005A1/en unknown
- 2018-01-08 ZA ZA2018/00129A patent/ZA201800129B/en unknown
- 2018-01-12 CO CONC2018/0000252A patent/CO2018000252A2/es unknown
- 2018-01-12 MX MX2023014146A patent/MX2023014146A/es unknown
- 2018-01-15 CL CL2018000124A patent/CL2018000124A1/es unknown
-
2019
- 2019-08-30 US US16/556,549 patent/US10639331B2/en active Active
- 2019-08-30 US US16/556,695 patent/US10568909B2/en active Active
- 2019-08-30 US US16/556,704 patent/US10639332B2/en active Active
- 2019-11-19 CL CL2019003311A patent/CL2019003311A1/es unknown
- 2019-11-19 CL CL2019003312A patent/CL2019003312A1/es unknown
- 2019-11-19 CL CL2019003310A patent/CL2019003310A1/es unknown
- 2019-11-19 CL CL2019003313A patent/CL2019003313A1/es unknown
-
2020
- 2020-01-31 US US16/777,919 patent/US10722538B2/en active Active
- 2020-03-24 JP JP2020052558A patent/JP7074367B2/ja active Active
- 2020-03-30 JP JP2020059702A patent/JP7239992B2/ja active Active
- 2020-04-06 JP JP2020068264A patent/JP7074369B2/ja active Active
- 2020-04-13 JP JP2020071602A patent/JP7074370B2/ja active Active
- 2020-04-20 JP JP2020074570A patent/JP7239993B2/ja active Active
- 2020-04-27 JP JP2020078116A patent/JP2020182458A/ja active Pending
- 2020-05-11 JP JP2020082964A patent/JP2020198875A/ja active Pending
- 2020-05-18 JP JP2020086514A patent/JP7205919B2/ja active Active
- 2020-05-25 JP JP2020090207A patent/JP2021000078A/ja active Pending
- 2020-06-15 AU AU2020203971A patent/AU2020203971B2/en not_active Ceased
- 2020-06-18 US US16/905,530 patent/US10881690B2/en active Active
- 2020-06-18 US US16/905,550 patent/US10888587B2/en not_active Expired - Fee Related
- 2020-06-18 US US16/905,499 patent/US10869897B2/en active Active
- 2020-09-08 CY CY20201100848T patent/CY1123505T1/el unknown
- 2020-10-13 AU AU2020256318A patent/AU2020256318A1/en not_active Abandoned
- 2020-12-09 US US17/116,635 patent/US11071756B2/en not_active Expired - Fee Related
- 2020-12-16 US US17/123,585 patent/US20210106624A1/en not_active Abandoned
-
2021
- 2021-04-30 US US17/245,012 patent/US20210252064A1/en not_active Abandoned
- 2021-04-30 US US17/245,133 patent/US11819518B2/en active Active
- 2021-04-30 US US17/245,031 patent/US11806366B2/en active Active
- 2021-04-30 US US17/245,105 patent/US11246889B2/en active Active
- 2021-04-30 US US17/245,076 patent/US11278571B2/en active Active
-
2022
- 2022-02-04 AU AU2022200745A patent/AU2022200745B2/en not_active Ceased
- 2022-10-17 US US18/047,234 patent/US20230241106A1/en not_active Abandoned
- 2022-10-17 US US18/047,195 patent/US20230190813A1/en not_active Abandoned
- 2022-10-17 US US18/047,236 patent/US20230241107A1/en not_active Abandoned
- 2022-10-21 US US18/048,489 patent/US20230285458A1/en not_active Abandoned
- 2022-10-21 US US18/048,796 patent/US20230201259A1/en not_active Abandoned
- 2022-10-24 US US18/049,105 patent/US20230086100A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020182458A5 (enExample) | ||
| JP2020198875A5 (enExample) | ||
| JP2020191862A5 (enExample) | ||
| JP2021101700A5 (enExample) | ||
| JP2024041841A5 (enExample) | ||
| JP2019513005A5 (enExample) | ||
| JP2019516663A5 (enExample) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| JP2020516681A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| JP2019515650A5 (enExample) | ||
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2019502360A5 (enExample) | ||
| JP2019536426A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2010527919A5 (enExample) | ||
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| HRP20210076T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma | |
| JP2019520038A5 (enExample) | ||
| HRP20210528T1 (hr) | Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma | |
| JP2020191868A5 (enExample) |